Article

Received 27.06.2025

Revised 30.09.2025

Accepted 12.12.2025

Retrieved from Vol. 1, No. 1, 2025

Pages 20 -28

Filin, A., Priputnevich, E., & Shishkina, V. (2025). Association of desmin expression with tumour size in colorectal carcinomas. Journal of Human Biology and Clinical Medicine, 1(1), 20-28. https://doi.org/10.63621/jhbcm/1.2025.20

Association of desmin expression with tumour size in colorectal carcinomas

Andrey Filin, Elena Priputnevich, Viktoria Shishkina

Desmin, which was expressed by muscle cells, myofibroblasts and certain pathological cells, remained poorly investigated in the context of the morphogenesis of colorectal cancer – the third most common oncological disease in the world. The aim of the study was to examine the characteristics of desmin expression in colorectal carcinomas and to compare the intensity of this expression with tumour nodule size. During the study, 24 samples of malignant large-intestinal tumours were subjected to histological examination and were stained using the immunohistochemical method with mouse monoclonal antibodies against desmin. Desmin expression was identified in all analysed samples. Desmin was expressed both within tumour structures and in the surrounding stromal tissue of the organ. Quantitative heterogeneity of desmin expression was revealed, ranging from extensive to scarce across different samples. When the volumetric density of desmin was compared with tumour nodule area, it was found that the overall amount of expressed desmin was statistically significantly higher in samples with large tumour nodules. In addition, a tendency was observed towards an increase in the amount of desmin localised within tumour structures with increasing tumour area. The study also included a comparison of the presence of desmin in the tumour with the size of the tumour conglomerate. It was established that desmin was present within the tumour considerably more often in large tumour nodules than in samples with small tumours. The findings obtained in the course of the study indicated a potential possibility of using desmin to assess the risk of tumour progression, as well as its potential use as a prognostic marker

tumour volume, intermediate filament protein, stroma, immunohistochemical method, tumour nodule
  1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. DOI: 10.3322/caac.21834
  2. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338–44. DOI: 10.1136/gutjnl-2022-327736
  3. Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology. 2020;158(2):341–53. DOI: 10.1053/j.gastro.2019.07.055
  4. Hu LF, Lan HR, Huang D, Li X-M, Jin KT. Personalized immunotherapy in colorectal cancers: Where do we stand? Front Oncol. 2021;11:76930. DOI: 10.3389/fonc.2021.769305
  5. Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: A comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7(3):262–74. DOI: 10.1016/S2468-1253(21)00426-X
  6. Meng Y, Wang B, Lin H, Li F, Lu S, Wang J, et al. Prognostic value of tumor size in colon cancer – smaller is better? Am Surg. 2023;89(12):6060–9. DOI: 10.1177/00031348231180944
  7. Saha S, Shaik M, Johnston G, Saha SK, Berbiglia L, Hicks D, et al. Tumor size predicts long-term survival in colon cancer: An analysis of the National Cancer Data Base. Am J Surg. 2015;209(3):570–4. DOI: 10.1016/j.amjsurg.2014.12.006
  8. Paulin D, Li Z. Desmin: A major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res. 2004;301(1):1–7. DOI: 10.1016/j.yexcr.2004.08.004
  9. Costa ML, Escaleira R, Cataldo A, Oliveira F, Mermelstein CS. Desmin: Molecular interactions and putative functions of the muscle intermediate filament protein. Braz J Med Biol Res. 2004;37(12):1819–30. DOI: 10.1590/S0100-879X2004001200007
  10. Arentz G, Chataway T, Price TJ, Izwan Z, Hardi G, Cummins AG, et al. Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clin Proteom. 2011;8(1):16. DOI: 10.1186/1559-0275-8-16
  11. Yoshida M, Suwa T, Shimada S, Shiotsuki K, Shigeta K, Nakamura H, et al. Desmin immunostaining is effective for improving interobserver variability in the depth assessment of the submucosal invasion of colorectal cancers. Hum Pathol. 2023;141:149–57.
  12. The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. [cited 2025 January 23]. Available from: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/
  13. Korzhevskii DE, editor. Morphological diagnostics. Preparation of material for histological examination and electron microscopy: A guide. Saint Petersburg: SpetsLit; 2013. 127 P.
  14. Buchwalow IB, Böcker W. Immunohistochemistry: Basics and methods. Berlin/Heidelberg: Springer; 2010. 153 P. DOI: 10.1007/978-3-642-04609-4
  15. Gomes G, Seixas MR, Azevedo S, Audi K, Jurberg AD, Mermelstein C, et al. What does desmin do: A bibliometric assessment of the functions of the muscle intermediate filament. Exp Biol Med. 2022;247(7):538–50. DOI: 10.1177/15353702221075035
  16. Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics. 2009;8(8):1878–90. DOI: 10.1074/mcp.M800541-MCP200
  17. Shin J, Wood LD, Hruban RH, Hong SM. Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers. PLoS One. 2020;15(11):e0242571. DOI: 10.1371/journal.pone.0242571
  18. Yan Q, Zhang K, Guo K, Liu S, Wasan HS, Jin H, et al. Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: A population-based study. Future Oncol. 2019;15(15):1745–58. DOI: 10.2217/fon-2018-0785
  19. Feng H, Lyu Z, Zheng J, Zheng C, Wu Q, Liang W, et al. Association of tumor size with prognosis in colon cancer: A Surveillance, Epidemiology, and End Results (SEER) database analysis. Surgery. 2021;169(5):1116–23. DOI: 10.1016/j.surg.2020.11.011
  20. Kato T, Alonso S, Muto Y, Perucho M, Rikiyama T. Tumor size is an independent risk predictor for metachronous colorectal cancer. Oncotarget. 2016;7(14):17896–904. DOI: 10.18632/oncotarget.7555
  21. Dai W, Li Y, Meng X, Cai S, Li Q, Cai G. Does tumor size have its prognostic role in colorectal cancer? Re-evaluating its value in colorectal adenocarcinoma with different macroscopic growth pattern. Int J Surg. 2017;45:105–12. DOI: 10.1016/j.ijsu.2017.07.100
  22.